R&D Pipeline
FibroGen is dedicated to creating innovative, first-in-class medicines for the treatment of chronic and life-threatening or debilitating conditions such as anemia in chronic kidney disease (CKD) and chemotherapy induced anemia (CIA), Duchenne muscular dystrophy (DMD), and locally advanced pancreatic cancer. The products we develop represent more than isolated opportunities or single indications — we see our products as representing broader platforms that enable us to continue to investigate discrete pathways and mediators that are central to multiple diseases.
HIF Platform
Preclinical
Phase 1
Phase 2
Phase 3
Approved
United States
ROXADUSTAT (HIF-PHI) ANEMIA OF CKD
CRL Received
China
Approved
Europe
Approved
Japan
Approved
1
FDA issued a complete response letter on 8/10/21
1
Phase 3
China
ROXADUSTAT (HIF-PHI) ANEMIA IN CIA
Fibrotic Disease Platform
Preclinical
Phase 1
Phase 2
Approved
Phase 3
Locally Advanced Pancreatic Cancer
Duchenne Muscular Dystrophy
PAMREVLUMAB
(ANTI-CTGF ANTIBODY)
Phase 3
Phase 3
PARTNERED
WHOLLY-OWNED
Roxadustat
Pamrevlumab
Pamrevlumab, our proprietary fully human antibody, represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body.
Roxadustat, an oral medicine, is the first in a new class of medicines, HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin.
Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority.
